Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 14/20 | 0.40 |
| ▸ | LPL | P06858 | 13/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13103886 | 0.97 | LIPG (0.42) | LIPGLPLDGAT1PRMT5WDR77 | |
| SCHEMBL21031685 | 0.97 | LIPG (0.42) | LIPGLPLDGAT1PRMT5WDR77 | |
| SCHEMBL22990007 | 0.97 | LIPG (0.42) | LIPGLPLDGAT1PRMT5WDR77 | |
| SCHEMBL13103915 | 0.97 | LIPG (0.42) | LIPGLPLDGAT1PRMT5WDR77 | |
| SCHEMBL13103907 | 0.97 | LIPG (0.42) | LIPGLPLDGAT1PRMT5WDR77 | |
| SCHEMBL20205740 | 0.97 | LIPG (0.42) | LIPGLPLDGAT1PRMT5WDR77 | |
| SCHEMBL22389178 | 0.95 | LIPG (0.44) | LIPGLPLDGAT1PDK2 | |
| SCHEMBL24257889 | 0.95 | LIPG (0.44) | LIPGLPLDGAT1PDK2 | |
| SCHEMBL26050388 | 0.95 | LIPG (0.44) | LIPGLPLDGAT1PDK2 | |
| SCHEMBL22990010 | 0.95 | LIPG (0.44) | LIPGLPLDGAT1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271989-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-08-31 | — | — | US | disclosed |
| US-20230271989-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-08-31 | — | — | US | disclosed |
| WO-2022034046-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271989-A1 | METAL COMPLEXES | AP3M1, AP1M1, AP2M1 | LIPG 3694/4885LPL 3235/4885DGAT1 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.